Migraine is a complex disorder that is developed due to the influence of lifestyle and environmental factors over multiple genes. The rising number of patients suffering from the migraine with brainstem aura is driving growth of the market. As per the Centers for Disease Control and Prevention (CDC), in 2015, about 9.7% of men and 20% of women age 18 years had a migraine.
Request Sample Copy:
Migraine with brainstem aura is termed for pain at the back of the head. The aura is a warning sign of a bad headache, dizziness, slurred speech, loss of balance, and vertigo. Migraine with brainstem aura generally occurs in women and men of all ages; however, adolescent girls are more susceptible to the disease.
However, risks of the possible side effects of the drugs taken to the treatment of migraine with brainstem aura such as sleepiness and fatigue, racing heartbeat, nausea, and difficulty in thinking are creating fear among patients, which are restraining growth of the global migraine with brainstem aura market. Nonetheless, the lack of proper medication for the treatment of disease and robust investment for drug development is likely to offer opportunities for growth in the coming years.
The key players operating in the global migraine with brainstem aura market include Merck & Co., Inc., Allergen Plc, Pfizer, Inc., Abbott Laboratories, GlaxoSmithKline Plc, AstraZeneca, Endo International Plc, Eisai Co., Ltd., Impax Laboratories, Johnson & Johnson, and Eli Lily and Company.
The migraine with brainstem aura market is segmented based on diagnosis, distribution channel, treatment, and end-user, and region.
In terms of diagnosis, the global migraine with brainstem aura market is categorized into computerized tomography (CT), magnetic resonance imaging (MRI), and others.
Based on the end-user, the market is segmented into diagnostic centers, hospital & clinics, and others.
Based on the distribution channel, the migraine with brainstem aura market is segmented into retail pharmacies, hospital pharmacies, and others.
Based on the treatment, the migraine with brainstem aura market is segmented into preventive medication and abortive medication. Of these, the abortive medication segment is sub-divided into anti-nausea medications, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The segment of preventive medication is sub-segmented into botox injections, antidepressants, and others.
Based on the region, the market is segmented into the Americas, Europe, Asia Pacific, and the Middle East, and Africa. Of these, the Americas region is estimated to hold a substantial share in the revenue of the migraine with brainstem aura market due to the presence of advanced developed healthcare infrastructure coupled with high healthcare investment in the region. Europe is estimated to hold a second-leading position in the global migraine with brainstem aura market owing to growing research activities and increasing healthcare expenditure in the region. additionally, increasing prevalence of the migraine with brainstem aura is augmenting investment for producing newer products is benefiting growth of the market in the region.
Asia Pacific region is estimated to expand at the most lucrative CAGR owing to the rising prevalence of migraines coupled with increasing government funding. Additionally, the presence of a robust population in the region and awareness regarding the availability of efficient treatment to handle the attack of migraines are augmenting growth of the global migraine with brainstem aura market.
Browse Complete Report with TOC at
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.